Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.73 |
| ▸ | C1R | P00736 | 6/20 | 0.67 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | C1S | P09871 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984780 | 0.85 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL4190607 | 0.83 | ELANE (0.79) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL29574035 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL9985824 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL9984683 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL29849973 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL9984776 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL9986142 | 0.77 | ELANE (1.00) | ELANEC1RPBRM1PRSS1 | |
| SCHEMBL5921024 | 0.77 | ELANE (0.76) | ELANEC1RPBRM1KMT2AMEN1 | |
| SCHEMBL6246926 | 0.76 | ELANE (0.73) | ELANEC1RPBRM1MAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | TLR8, TLR7, TLR3 | ELANE 99/4885C1R 2352/4885PBRM1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.